search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.

Mustapha Abubakar ,
Jenny Chang-Claude ,
H Raza Ali ,
Nilanjan Chatterjee ,
Penny Coulson ,
Frances Daley ,
Fiona Blows ,
Javier Benitez ,
Roger L Milne ,
Hermann Brenner ,
Christa Stegmaier ,
Arto Mannermaa ,
Anja Rudolph ,
Peter Sinn ,
Fergus J Couch ,
Peter Devilee ,
Rob A E M Tollenaar ,
Caroline Seynaeve ,
Jonine Figueroa ,
Jolanta Lissowska ,
Stephen Hewitt ,
Maartje J Hooning ,
Antoinette Hollestelle ,
Renée Foekens ,
Linetta B Koppert ,
,
Manjeet K Bolla ,
Qin Wang ,
Michael E Jones ,
Minouk J Schoemaker ,
Renske Keeman ,
Douglas F Easton ,
Anthony J Swerdlow ,
Mark E Sherman ,
Marjanka K Schmidt ,
Paul D Pharoah ,
Montserrat Garcia-Closas

Abstract

Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1 = 1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1 = 1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1 = 0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.

More about this publication

International journal of cancer

Volume 143
Issue nr. 4
Pages 746-757
Publication date 15-08-2018

Full text links

Publisher website (DOI) 10.1002/ijc.31352
Europe PubMed Central 29492969
Pubmed 29492969

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.